NCT06393517View on ClinicalTrials.gov

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Healthy Participants
Interventions
DRUG

PF-06954522 IR (Formulation 1)

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

DRUG

PF-06954522 MR (Formulation 2)

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

DRUG

PF-06954522 MR (Formulation 3)

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Trial Locations (2)

06511

Pfizer Clinical Research Unit - New Haven, New Haven

Pfizer Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06393517 - A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults | Biotech Hunter | Biotech Hunter